Navigation Links
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
Date:3/16/2009

Dr. James Cai, President of Hong Kong-based subsidiary Pangu BioPharma to Speak

SAN DIEGO, March 16 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, announced today that it will participate at the ChinaBio(R) Investor Forum in Hong Kong on 19 March 2009. Dr. James Cai, Senior Vice President of Clinical Development a aTyr Pharma and President of the Hong Kong based subsidiary Pangu BioPharma, will give an overview of aTyr's Discovery and Development program in the afternoon on Thursday, March 19th. The event will take place at the Hong Kong Science Park (http://www.chinabiollc.com/events/CBIF2009-HK/overview).

"aTyr Pharma and its Hong Kong subsidiary, Pangu BioPharma, are exactly the types of companies we seek out to present at our events," said Greg Scott, president and founder of ChinaBio LLC, organizer of the ChinaBio(R) Investor Forums. "aTyr's platform is strongly rooted in novel science, and Pangu is leveraging the best of China and Hong Kong through its research efforts here. We expect that aTyr will be very attractive to the over 50 VCs attending the Investor Forum."

aTyr has successfully raised Series A and Series B funds from leading U.S. based venture capital firms, including Alta Partners, Cardinal Partners and Polaris Venture Partners. In addition to supporting the company's continued platform discovery efforts, aTyr's management team is also preparing for preclinical development and Phase I studies for their first biologics drug candidate.

aTyr Pharma and Pangu BioPharma have a novel platform of naturally occurring protein fragments that can be developed into biologic agents for treating a wide variety of diseases. Capitalizing on t
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
2. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
3. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
6. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
7. BioCis Pharma Starts Phase IIa Trial in Psoriasis
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
10. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... LLC , a software company in Waukesha that sells home ... programs, said on Thursday it has been acquired by a ... it would expand its offerings to manufacturers and retailers by ... and product pictures. Big Hammer operates one of 11 authorized ...
... In the same week that state senators in Wisconsin ... to include ethanol, policymakers in another Midwestern state were ... , ,Agri-business giant Louis Dreyfus Corp. announced it ... northern Indiana, where it plans to crush nearly 50 ...
... company in central Wisconsin has announced its plans ... offerings of high-speed Internet and voice over IP services. ... serves about 28,000 customers. CEO Douglas Wenzlaff told reporters ... Madison and Eau Claire. Its existing base is in ...
Cached Biology Technology:Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 2Ethanol bill's death in Wisconsin ignores what's happening with our neighbors 3
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... in those green coffee bean dietary supplements often touted ... obese laboratory mice fed a high-fat diet when given at ... in ACS, Journal of Agricultural and Food Chemistry . ... fat in the liver. Vance Matthews, Kevin Croft ...
... 2013: A new study presented today at EULAR 2013, ... shows that one in eight patients at risk of ... over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat ... NSAID users, over one-third had taken the medication for ...
... show ways in which we can markedly improve drug targeting ... imaging techniques. In real time and in three dimensions, ... active cancer cells respond to a particular drug. They can ... to administer drugs. Finally, using preclinical models of the disease, ...
Cached Biology News:Patients use OTC NSAIDs even when they have a high risk of serious side effects 2Nanotechnology helps track and improve drug action in pancreatic cancer 2
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... Imaging's proprietary Focus™ detector technology, while precisily ... R4. The microPET Focus 120 offers ... PET scanner. Focus scanners also possess ... based PETsystems. The combination of high ...
... This product has been developed to ... peroxidase labeled proteins. Stability is increased ... to 2-8 centigrade. This product is ... no mercury or azide. This formulation ...
Biology Products: